The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
Acute antibody-mediated rejection
Acute cellular rejection
Children
Donor-specific antibodies
Kidney transplantation
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
27
05
2019
accepted:
03
01
2020
revised:
16
12
2019
pubmed:
18
2
2020
medline:
5
5
2021
entrez:
18
2
2020
Statut:
ppublish
Résumé
The longitudinal relationship between HLA class I and II eplet mismatches, de novo donor-specific antibodies (dnDSA) development, and acute rejection after transplantation in childhood is unknown. Eplet mismatches at HLA class I and II loci were calculated retrospectively for each donor/recipient pair transplanted between 2005 and 2015 at a single Australian center. Logistic regression analyses were conducted to determine the association between the number of eplet mismatches, dnDSA, and acute rejection. The cohort comprised 59 children (aged 0-18 years) who received their first kidney allograft and were followed for median (interquartile range) 4.5 (± 2.6) years. Overall, 32% (19/59) developed dnDSA (class I 3% (2/59), class II 14% (8/59), 15% class I and II (9/59)), and 24% (14/59) developed biopsy-proven acute rejection. Every unit increase in class I and II eplet mismatches corresponded to an increase in risk of class I (odds ratio (OR) 1.22, 95% CI 1.07-1.39, p < 0.01) and class II (OR 1.06, 95% CI 1.01-1.11, p = 0.02) dnDSA development. Compared with recipients without dnDSA, class I and II dnDSA were associated with direction of effect towards increased risk of acute cellular rejection (class I: OR 5.87, 95% CI 0.99-34.94, p = 0.05; class II: OR 12.00, 95% CI 1.25-115.36, p = 0.03) and acute antibody-mediated rejection (class I: OR 25.67, 95% CI 3.54-186.10, p < 0.01; class II: OR 9.71, 95% CI 1.64-57.72, p = 0.01). Increasing numbers of HLA class I or II eplet mismatches were associated with the development of dnDSA. Children who developed dnDSA were also more likely to develop acute rejection compared with children without dnDSA.
Sections du résumé
BACKGROUND
The longitudinal relationship between HLA class I and II eplet mismatches, de novo donor-specific antibodies (dnDSA) development, and acute rejection after transplantation in childhood is unknown.
METHODS
Eplet mismatches at HLA class I and II loci were calculated retrospectively for each donor/recipient pair transplanted between 2005 and 2015 at a single Australian center. Logistic regression analyses were conducted to determine the association between the number of eplet mismatches, dnDSA, and acute rejection.
RESULTS
The cohort comprised 59 children (aged 0-18 years) who received their first kidney allograft and were followed for median (interquartile range) 4.5 (± 2.6) years. Overall, 32% (19/59) developed dnDSA (class I 3% (2/59), class II 14% (8/59), 15% class I and II (9/59)), and 24% (14/59) developed biopsy-proven acute rejection. Every unit increase in class I and II eplet mismatches corresponded to an increase in risk of class I (odds ratio (OR) 1.22, 95% CI 1.07-1.39, p < 0.01) and class II (OR 1.06, 95% CI 1.01-1.11, p = 0.02) dnDSA development. Compared with recipients without dnDSA, class I and II dnDSA were associated with direction of effect towards increased risk of acute cellular rejection (class I: OR 5.87, 95% CI 0.99-34.94, p = 0.05; class II: OR 12.00, 95% CI 1.25-115.36, p = 0.03) and acute antibody-mediated rejection (class I: OR 25.67, 95% CI 3.54-186.10, p < 0.01; class II: OR 9.71, 95% CI 1.64-57.72, p = 0.01).
CONCLUSIONS
Increasing numbers of HLA class I or II eplet mismatches were associated with the development of dnDSA. Children who developed dnDSA were also more likely to develop acute rejection compared with children without dnDSA.
Identifiants
pubmed: 32065279
doi: 10.1007/s00467-020-04474-x
pii: 10.1007/s00467-020-04474-x
doi:
Substances chimiques
HLA Antigens
0
Isoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1061-1068Références
Transplantation. 2013 Jun 15;95(11):1360-8
pubmed: 23549198
Am J Transplant. 2018 Feb;18(2):293-307
pubmed: 29243394
Front Immunol. 2018 Aug 31;9:2010
pubmed: 30233594
Transplantation. 2016 May;100(5):1094-102
pubmed: 26901078
Am J Transplant. 2015 Aug;15(8):2197-202
pubmed: 26095765
Am J Transplant. 2013 Dec;13(12):3114-22
pubmed: 24164958
Transplantation. 2004 Apr 27;77(8):1236-9
pubmed: 15114091
Kidney Int. 2014 Nov;86(5):1039-48
pubmed: 24717292
Curr Opin Organ Transplant. 2014 Aug;19(4):428-35
pubmed: 25010064
Nephrol Dial Transplant. 2017 Nov 1;32(11):1949-1956
pubmed: 28992338
Clin Transplant. 2016 Jan;30(1):71-80
pubmed: 26529289
Pediatrics. 2014 Apr;133(4):594-601
pubmed: 24616363
Oncotarget. 2018 Feb 1;9(17):13116-13124
pubmed: 29568344
Am J Transplant. 2015 Jan;15(1):137-48
pubmed: 25521856
Transplantation. 2018 Aug;102(8):1338-1343
pubmed: 29443827
Pediatr Nephrol. 2017 Oct;32(10):1861-1869
pubmed: 27995324
Transplantation. 2013 Jan 15;95(1):19-47
pubmed: 23238534
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Hum Immunol. 2006 Nov;67(11):847-62
pubmed: 17145365